深圳细胞谷团队赴广州生物岛实验室、广医联合生科院交流访问

 
On the morning of January 10, 2024, Wang Jianxun, Chief scientist of Shenzhen Cell Valley, Xiang Hua, Deputy General manager of Shenzhen Cell Valley, Zhao Lijun, head of research and development, Yang Jianglong, Vice minister of Marketing Department, visited Guangzhou Bioisland Laboratory and had a discussion with Professor Liu Huisheng and other laboratory backbone. At the symposium, the two sides had in-depth exchanges on the latest research progress of tumor cell immunotherapy and the direction of cooperation. Professor Wang Jianxun, chief scientist of our company, introduced the development of Shenzhen Cell Valley and the advantages of retrovirus vectors for the preparation of CAR-NK cells. Professor Liu Huisheng introduced the research direction of the team and led a visit to Guangzhou Bioisland Laboratory. Professor Liu Huisheng showed great interest in our company's NK cell preparation project, and said that after the Spring Festival, he would work together to "preclinical research on the treatment of lung cancer based on NK cell therapy".

In the afternoon of the same day, the team led by Professor Gu Jianxun of Shenzhen Cell went to Guangzhou Medical University - Guangzhou Institute of Biomedicine and Health of the Chinese Academy of Sciences Joint School of Life Sciences (hereinafter referred to as "Guangzhou Medical Joint School of Health") for an exchange visit. General Party Branch Secretary Fang Shaoyuan, Deputy Party Branch Secretary Chen Xiangyi, Deputy President Dai Jianwei, Deputy president Zhang Xiaoren, Deputy President Gong Qing, Director of Biochemistry and Molecular Biology Teaching and Research Department, Director Ouyang Yongchang, Director of Biotechnology Department Su Xiaobo, director of General Management Office Tan Yin warmly hosted and opened the discussion meeting. We discussed the joint development direction.

At the symposium, Gong Qing, vice president of the Medical College of Guangzhou Medical Union, and Professor Wang Jianxun of Shenzhen Cell Valley successively introduced the development of their respective companies and the advantages of team development. The two sides conducted in-depth discussions on the development status of cellular immunotherapy, the advantages of retrovirus, the latest research progress of TCR-T therapy, the combination of industry-university-research, school-enterprise cooperation, and joint training of interns. The two sides jointly paid attention to the problems of students' study and employment, and the United College of Health and Sciences also invited Professor Wang Jianxun to carry out theoretical courses such as lectures on cutting-edge cell therapy in Guangzhou Medical University.

Subsequently, the Cell Valley team visited the teaching laboratory and the science and technology building laboratory under the leadership of Vice President Gong Qing.

Professor Wang Jianxun said that talent is one of the most important supporting factors for the development of the emerging industry of cell and gene therapy. Under the leadership of the General Party Branch Secretary Fang Shaoyuan, GMU has cultivated a batch of high-level talents, providing strong talent support for the development of the biomedical industry; Shenzhen Cell Valley has a mature talent training model, and will continue to build an open, innovative and collaborative talent training platform to provide more growth space and platform resources for technical talents in the field of cell and gene therapy. At the same time, the two sides will cooperate in joint research on TCR-T based on retroviral vectors, and jointly break through more technical barriers to benefit more cancer patients.

The exchange prompted the two sides to reach an agreement and lay a solid foundation for the cooperation between the two sides. Shenzhen Cell Valley and Guangzhou Medical University will work together to create a talent training mechanism for the industry and jointly help the development of China's cell and gene therapy industry!